Shared on 31 Jul 25
Fair value Increased 83%Neimeth Pharmaceuticals Delivers Strong Turnaround in H1 2025 Despite Financing Cost Pressures Neimeth International Pharmaceuticals Plc posted a robust recovery in its half-year 2025 earnings, underpinned by strong revenue growth and operational efficiency, despite the lingering drag of elevated finance costs. Key Highlights: Revenue Surge : Neimeth reported a 76% year-on-year increase in revenue to ₦2.91 billion in H1 2025, up from ₦1.66 billion in H1 2024.
Shared on 21 Jul 25
Fair value Increased 34%WaneInvestmentHouse has increased future PE multiple from 22.3x to 25.0x and decreased discount rate from 24.5% to 20.0%.
Shared on 27 Jun 25
WaneInvestmentHouse made no meaningful changes to valuation assumptions.
Shared on 25 Jun 25
Subject: Neimeth Delivers Strong Revenue Growth and Operational Turnaround Despite Persistent Bottom-Line Pressure Neimeth International Pharmaceuticals Plc has reported a remarkable 103% year-on-year revenue growth , signaling a strong rebound in commercial performance during the 2024 financial year. Revenue surged from N2.21 billion in 2023 to N4.49 billion , driven by higher sales volumes and deeper market penetration , according to Chairman Christopher Oshiafi at the company’s 66th Annual General Meeting in Lagos.
Shared on 24 Jun 25
WaneInvestmentHouse has decreased revenue growth from 21.2% to 0.0% and decreased shares outstanding growth rate from 0.0% to 0.0%.